Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injection

New Delhi, Jan 10 (PTI) Glenmark Pharmaceuticals Ltd on Tuesday said its US arm has launched its generic version of diuretic Bumetanide injection.

In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.

These are the generic version of Bumex injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC, it added.

The launch affirms commitment to Glenmark’s continued focus on institutional business, company Senior Vice President, Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan said.

The Bumex injection, 0.25 mg/mL achieved annual sales of approximately USD 16.5 million, the company said citing IQVIA sales data for the 12-month period ended November 2022.